New publication shows Cline’s gradient surfaces achieving faster and more efficient stem cell differentiation
In a new article published in the Journal of Biotechnology, Cline Scientific showed that gradient surfaces functionalized with Activin-A leads to improved, controllable and more efficient differentiation of stem cells compared to classical methods.
Activin-A is an important biomolecule for the differentiation of stem cells into many different types of cells and organs. The team transformed induced pluripotent stem cells (iPSCs) into definitive endoderm (DE) which is the first step in generating many different cell linages and stem cell based applications. Cline's method not only allowed for quicker and more efficient results but also allows for finding the optimal activin density in vitro.
These exciting findings, in combination with previously communicated results, further confirm the relevance and potential of Cline’s gradient nanotechnology in range of biomolecules and biological processes. Precise and efficient methods for differentiating stem cells into targeted development stages is crucial for cell therapies such as StemCART, Cline's stem cell therapy for arthritis.
The full publication can be found at the following link. https://www.sciencedirect.com/science/article/abs/pii/S0168165620303011
For more information, please contact:
Hanne Evenbratt, Director Product Development
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23
Kort om Cline Scientific
Cline Scientific utvecklar avancerad cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt inom dessa områden via samarbeten med läkemedelsföretag och akademiska forskningsinstitutioner på global basis. Fokus på projekt inom diagnostik för metastaserande cancer samt utveckling av stamcellsterapier har valts eftersom Clines nanoteknologi här erbjuder nya lösningar på hittills olösta svårigheter. Bolagets unika, patenterade teknologi används i cellbaserade produkter och processer för att driva Life Science projekt till och genom klinisk fas.